Search

Your search keyword '"Miyagi Y"' showing total 1,093 results
Start Over Author "Miyagi Y"
1,093 results on '"Miyagi Y"'

52. Study of Neutral Kaon Photo-Production at LNS-Tohoku

Author

Bydžovský, P., Chiga, N., Fujii, Y., Futatsukawa, K., Han, Y.C., Hashimoto, O., Hirose, K., Hosomi, K., Iguchi, A., Ishikawa, T., Kanda, H., Kaneta, M., Kawai, M., Kawasaki, T., Kawama, D., Kiyokawa, S., Koike, T., Konno, O., Ma, Y., Maeda, K., Maruyama, N., Matsumura, A., Mimori, M., Miwa, K., Miyagi, Y., Nakamura, S.N., Ohtani, T., Okayasu, Y., Sasaki, A., Shimizu, H., Shirotori, K., Sotona, M., Suzuki, K., Tamae, T., Tamura, H., Terada, N., Tsukada, K., Wang, T.S., Yamamoto, T., Yamazaki, H., and Yokota, K.

Published
2008

53. The possibility of personalized chemotherapy for non-small cell lung cancer using interactome analyses of PDX/NOG models

Author

Chijiwa, T., primary, Komura, D., additional, Haraguchi, M., additional, Noguchi, A., additional, Sato, H., additional, Ito, H., additional, Nakayama, H., additional, Katayama, M., additional, Miyao, N., additional, Suemizu, H., additional, Nakamura, Y., additional, Furukawa, D., additional, Moriya, T., additional, Isagawa, T., additional, Katoh, H., additional, Ishikawa, S., additional, Nakamura, M., additional, and Miyagi, Y., additional

Published
2017
Full Text
View/download PDF

55. 24P Establishment of patient-derived xenografts from malignant pleural effusion using NOG mice

Author

Chijiwa, T., primary, Haraguchi, M., additional, Isagawa, T., additional, Noguchi, A., additional, Katayama, M., additional, Miyao, N., additional, Yoshioka, M., additional, Matsui, N., additional, Tateishi, Y., additional, Suemizu, H., additional, Yamada, R., additional, Nakamura, Y., additional, Imai, K., additional, Komura, D., additional, Katoh, H., additional, Ishikawa, S., additional, Nakamura, M., additional, and Miyagi, Y., additional

Published
2016
Full Text
View/download PDF

56. 65PD Significance of preoperative fine-needle aspiration biopsy for suspected cases of lymph node metastasis in primary breast cancer

Author

Ogiya, A., primary, Iwase, T., additional, Teruya, N., additional, Sakamoto, H., additional, Nakashima, E., additional, Kataoka, A., additional, Kitagawa, D., additional, Sakai, T., additional, Morizono, H., additional, Miyagi, Y., additional, Horii, R., additional, Akiyama, F., additional, and Ohno, S., additional

Published
2016
Full Text
View/download PDF

61. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study (vol 108, pg 1495, 2013)

Author

van Grieken, N.C.T., Aoyama, T., Chambers, P., Bottomley, D., Ward, L., Inam, I., Buffart, T., Das, K., Lim, T., Pang, B., Zhang, S., Tan, I., Carvalho, B., Heideman, D.A.M., Miyagi, Y., Kameda, Y., Arai, T., Meijer, G.A., Tsuburaya, A., Tan, P., Yoshikawa, T., Grabsch, H., I, Pathology, and CCA - Disease profiling

Published
2014

62. Assessment of Myometrial Invasion at the Invasion Site of an Endometrial Carcinoma by Ultrasonography Along with an Intrauterine Catheter

Author

Junichi Kodama, Yasunari Miyagi, Mitsuo Yoshinouchi, Miyagi Y, Atsushi Hongo, Kunihiro Kawanishi, Junko Yamamoto, Yuji Kobashi, Ilse A. Perdomo, Shinako Yamada, and Takafumi Kudo

Subjects
Adult, Gynecology, medicine.medical_specialty, Transvaginal ultrasonography, business.industry, Endometrial cancer, Myometrium, Obstetrics and Gynecology, Middle Aged, medicine.disease, Sensitivity and Specificity, Catheterization, Endometrial Neoplasms, Catheter, Carcinoma, medicine, Humans, Female, Neoplasm Invasiveness, Ultrasonography, business, Aged
Abstract

Objectives: To evaluate by transvaginal ultrasonography (TVU) the thickness of the intact myometrium at the presumed tumor-origin site and to establish criteria for a half myometrial invasion. Methods: A total of 19 successive patients with endometrial cancer who were treated between January 1, 1997, and January 31, 1998, participated in this study. TVU mode B with and without the use of an intrauterine silicon catheter was performed. Results: Using a catheter, the origin site was correctly detected in 15 cases (79%). The best criterion for half myometrial invasion was a 6-mm thickness of the intact myometrium at the origin site. The sensitivity/specificity/accuracy of TVU with the use of a catheter in cases with the correct estimated origin site, were 1.00/0.67/0.86 for myometrial invasion < 1/2, and 0.67/1.00/0.86 for myometrial invasion < 1/2. Conclusion: It is of value to use 6-mm as the criterion for the thickness of the intact myometrium at the estimated tumor-origin site in connection with TVU with the use of a catheter for preoperatively assessing half myometrial invasion.

Published
1999

63. Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: an exploratory study of the randomized phase II COMPASS trial

Author

Tanabe, K., primary, Yoshikawa, T., additional, Oshima, T., additional, Miyagi, Y., additional, Morita, S., additional, Nishikawa, K., additional, Ito, Y., additional, Matsui, T., additional, Kimura, Y., additional, Aoyama, T., additional, Hayashi, T., additional, Ogata, T., additional, Cho, H., additional, Tuburaya, A., additional, and Sakamoto, J., additional

Published
2016
Full Text
View/download PDF

65. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

Author

Lin, SJ, Gagnon-Bartsch, JA, Tan, IB, Earle, S, Ruff, L, Pettinger, K, Ylstra, B, van Grieken, N, Rha, SY, Chung, HC, Lee, J-S, Cheong, JH, Noh, SH, Aoyama, T, Miyagi, Y, Tsuburaya, A, Yoshikawa, T, Ajani, JA, Boussioutas, A, Yeoh, KG, Yong, WP, So, J, Lee, J, Kang, WK, Kim, S, Kameda, Y, Arai, T, zur Hausen, A, Speed, TP, Grabsch, HI, Tan, P, Lin, SJ, Gagnon-Bartsch, JA, Tan, IB, Earle, S, Ruff, L, Pettinger, K, Ylstra, B, van Grieken, N, Rha, SY, Chung, HC, Lee, J-S, Cheong, JH, Noh, SH, Aoyama, T, Miyagi, Y, Tsuburaya, A, Yoshikawa, T, Ajani, JA, Boussioutas, A, Yeoh, KG, Yong, WP, So, J, Lee, J, Kang, WK, Kim, S, Kameda, Y, Arai, T, zur Hausen, A, Speed, TP, Grabsch, HI, and Tan, P

Abstract

OBJECTIVE: Differences in gastric cancer (GC) clinical outcomes between patients in Asian and non-Asian countries has been historically attributed to variability in clinical management. However, recent international Phase III trials suggest that even with standardised treatments, GC outcomes differ by geography. Here, we investigated gene expression differences between Asian and non-Asian GCs, and if these molecular differences might influence clinical outcome. DESIGN: We compared gene expression profiles of 1016 GCs from six Asian and three non-Asian GC cohorts, using a two-stage meta-analysis design and a novel biostatistical method (RUV-4) to adjust for technical variation between cohorts. We further validated our findings by computerised immunohistochemical analysis on two independent tissue microarray (TMA) cohorts from Asian and non-Asian localities (n=665). RESULTS: Gene signatures differentially expressed between Asians and non-Asian GCs were related to immune function and inflammation. Non-Asian GCs were significantly enriched in signatures related to T-cell biology, including CTLA-4 signalling. Similarly, in the TMA cohorts, non-Asian GCs showed significantly higher expression of T-cell markers (CD3, CD45R0, CD8) and lower expression of the immunosuppressive T-regulatory cell marker FOXP3 compared to Asian GCs (p<0.05). Inflammatory cell markers CD66b and CD68 also exhibited significant cohort differences (p<0.05). Exploratory analyses revealed a significant relationship between tumour immunity factors, geographic locality-specific prognosis, and postchemotherapy outcomes. CONCLUSIONS: Analyses of >1600 GCs suggest that Asian and non-Asian GCs exhibit distinct tumour immunity signatures related to T-cell function. These differences may influence geographical differences in clinical outcome, and the design of future trials particularly in immuno-oncology.

Published
2015

71. γ-ray spectroscopy study of Λ 11 B and Λ 12 C

Author

Ma, Y., primary, Ajimura, S., additional, Aoki, K., additional, Dairaku, M., additional, Fu, Y. Y., additional, Fujioka, H., additional, Fukuda, T., additional, Futatsukawa, K., additional, Hosomi, K., additional, Imoto, W., additional, Kawai, M., additional, Kakiguchi, Y., additional, Kinoshita, S., additional, Koike, T., additional, Maruyama, N., additional, Mimori, M., additional, Minami, S., additional, Miura, Y., additional, Miwa, K., additional, Miyagi, Y., additional, Nagae, T., additional, Nakajima, D., additional, Noumi, H., additional, Shirotori, K., additional, Suzuki, T., additional, Takahashi, T., additional, Takahashi, T. N., additional, Tamura, H., additional, Tanida, K., additional, Terada, N., additional, Toyoda, A., additional, Tsukada, K., additional, Ukai, M., additional, and Zhou, S. H., additional

Full Text
View/download PDF

74. Erratum: KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

Author

van Grieken, N C T, primary, Aoyama, T, additional, Chambers, P A, additional, Bottomley, D, additional, Ward, L C, additional, Inam, I, additional, Buffart, T E, additional, Das, K, additional, Lim, T, additional, Pang, B, additional, Zhang, S L, additional, Tan, I B, additional, Carvalho, B, additional, Heideman, D A M, additional, Miyagi, Y, additional, Kameda, Y, additional, Arai, T, additional, Meijer, G A, additional, Tsuburaya, A, additional, Tan, P, additional, Yoshikawa, T, additional, and Grabsch, H I, additional

Published
2014
Full Text
View/download PDF

76. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters

Author

Junko Yamamoto, Kunihiro Kawanishi, Takafumi Kudo, Miyagi Y, Junichi Kodama, Atsushi Hongo, Mitsuo Yoshinouchi, Keiichiro Nakamura, and Yasunari Miyagi

Subjects
Cancer Research, Organoplatinum Compounds, DNA damage, Stereochemistry, Cell Survival, Antineoplastic Agents, Pharmacology, Biology, Toxicology, Colony-Forming Units Assay, chemistry.chemical_compound, Pharmacokinetics, In vivo, DNA Crosslinking, Tumor Cells, Cultured, Humans, Pharmacology (medical), Nedaplatin, Ovarian Neoplasms, Biological activity, DNA, Neoplasm, In vitro, Culture Media, Cross-Linking Reagents, Oncology, chemistry, Pharmacodynamics, Area Under Curve, Female, DNA Damage, Half-Life
Abstract

Purpose: The pharmacodynamic effects of cis-diammine(glycolato)platinum (nedaplatin, 254-S) in vitro have been reported, but the dosage and exposure time in vitro have not always been based on clinical observations of the drug's actions in vivo. Regardless of the actual exposure conditions used, the effect of cell-cycle nonspecific anticancer agents such as nedaplatin is believed to depend on the area under the drug concentration-time curve (AUC). In this study, we evaluated the pharmacodynamics of nedaplatin in vitro, especially in relation to its AUC dependency, in terms of cell survival and DNA crosslinking. Methods: BG-1 human ovarian cancer cells were treated with various concentrations of nedaplatin to simulate the pharmacokinetics of administration in a clinical setting. The BG-1 cells were exposed to nedaplatin dissolved in medium containing serum using constant concentration conditions, either high (maximum 7.69 mg/l) or low (average 1.33 mg/l). These concentrations were based on doses used in clinical studies. We then adjusted the exposure conditions in vitro to simulate the elimination of the drug from serum in vivo as follows: T1/2 α 1.20 h and T1/2 β 2.70 h. The AUC values were set at 4, 8, 16, 25 and 40 mg·h/l for all exposure conditions. A colony-formation assay for the surviving fraction and an alkaline-elution assay for DNA crosslink measurement were done for the pharmacodynamic evaluation with comparison on the basis of the AUC value. Results: Exposure to a low concentration for a long time was the most effective of the exposure conditions at the same AUC value. The greater the AUC value, the higher the crosslink index under all exposure conditions. This index tended to increase particularly after exposure to the low concentration. The natural logarithm of the surviving fraction (Y′) was a linear function of the crosslink index regardless of the drug-exposure condition: ln(Y′)=-87.2x+ln(5.79), R 2=0.89. The threshold cytocidal effect was associated with a crosslink index of 0.02. Conclusion: There was a strong correlation between the cytocidal effect of nedaplatin and DNA crosslink formation. The cytocidal effect and DNA crosslinking in vitro depended on the exposure conditions used to define the AUC. Therefore, a new pharmacokinetic-pharmacodynamic model for nedaplatin must be constructed to investigate the most effective administration procedure in vivo.

Published
2001

77. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer

Author

Mitsuo Yoshinouchi, Takafumi Kudo, Miyagi Y, Akihiko Seki, Junichi Kodama, and Noriko Seki

Subjects
Adult, Cancer Research, Time Factors, Receptor, ErbB-2, Fibroblast Growth Factor 3, Biology, Proto-Oncogene Proteins, Gene duplication, medicine, Carcinoma, Biomarkers, Tumor, Humans, Gene, Aged, Neoplasm Staging, Ovarian Neoplasms, Oncogene, Gene Amplification, Cancer, Cell cycle, Genes, erbB-2, Middle Aged, medicine.disease, Molecular biology, Molecular medicine, Fibroblast Growth Factors, Survival Rate, Serous fluid, Oncology, CA-125 Antigen, Cancer research, Female, Follow-Up Studies
Abstract

We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.

Published
2000

78. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer

Author

Atsushi Hongo, Miyagi Y, Mitsuo Yoshinouchi, Noriko Seki, Takafumi Kudo, and Junichi Kodama

Subjects
Vascular Endothelial Growth Factor A, Cancer Research, Pathology, medicine.medical_specialty, Platelet-derived growth factor, Angiogenesis, Endothelial Growth Factors, Biology, Endometrium, chemistry.chemical_compound, medicine, Humans, RNA, Messenger, Microvessel, Neoplasm Staging, Lymphokines, Thymidine Phosphorylase, Neovascularization, Pathologic, Reverse Transcriptase Polymerase Chain Reaction, Vascular Endothelial Growth Factors, Endometrial cancer, Microcirculation, medicine.disease, Immunohistochemistry, Endometrial Neoplasms, Vascular endothelial growth factor, medicine.anatomical_structure, Real-time polymerase chain reaction, Oncology, chemistry, Female, Blood vessel
Abstract

Although many angiogenic factors have been described, it is not well defined which factors are expressed in endometrial cancer. The object of this study was to examine mRNA levels of the two angiogenic factors, vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) in endometrial cancer tissues and their association with clinicopathological features including microvessel density. The level of VEGF and PD-ECGF mRNAs was assessed by semi-quantitative reverse transcription-polymerase chain reaction using beta-actin as an internal standard in 38 patients with endometrial cancer. Microvessel counts were also assessed by immunostaining for factor VIII-related antigen in the most vascularised area of the specimen. VEGF/beta-actin ratios of non-endometrioid tumours were significantly higher than those of endometrioid tumours (P = 0.013). VEGF/beta-actin ratios of cases with lymph-vascular space involvement were significantly higher than those of cases without lymph-vascular space involvement (P = 0.021). Although it was not statistically significant, PD-ECGF/beta-actin ratios in grade 3 tumours were higher than those in grade 1 and 2 tumours (P = 0.066). The microvessel density was significantly correlated with the level of VEGF and PD-ECGF mRNA expression (P = 0.041 and P0.0001, respectively). Our findings provide evidence that the expression of both VEGF and PD-ECGF is involved in the promotion of angiogenesis in endometrial cancer. In addition, VEGF and PD-ECGF might contribute to the aggressive potential of high grade tumours or certain histological subtypes with unfavourable prognosis through the induction of angiogenesis.

Published
2000

79. Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer

Author

Junichi Kodama, Mitsuo Yoshinouchi, Noriko Seki, Takafumi Kudo, Atsushi Hongo, Hiroyuki Okuda, Keizo Tokumo, and Miyagi Y

Subjects
Cervical cancer, Thymidine Phosphorylase, Cancer Research, Pathology, medicine.medical_specialty, Neovascularization, Pathologic, Oncogene, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis, Uterine Cervical Neoplasms, Cancer, General Medicine, Biology, medicine.disease, Immunohistochemistry, Metastasis, Oncology, Epidermoid carcinoma, Tumor progression, Disease Progression, medicine, Humans, Adenocarcinoma, Female, RNA, Messenger
Abstract

We examined the expression of platelet-derived endothelial cell growth factor (PD-ECGF) mRNAs in 47 invasive cervical cancer tissues by semi-quantitative RT-PCR and addressed its association with clinicopathological features including microvessel density. Squamous cell carcinomas expressed higher levels of PD-ECGF mRNA than non-squamous cell carcinomas (P=0.014). We found no association between FIGO stage and levels of PD-ECGF mRNA. A subset of 31 patients with stage Ib-II cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy. There were no significant differences in PD-ECGF mRNA levels with respect to tumor size, degree of stromal invasion, lymphvascular space involvement, parametrial involvement, vaginal involvement or lymph node metastasis among these patients. There was no correlation between microvessel density and the levels of PD-ECGF mRNA. These findings suggest that PD-ECGF expression is not associated with progression and metastasis of cervical cancer.

Published
1999

80. Malignant melanoma of the uterine cervix: a case report

Author

Shinako Yamada, Miyagi Y, Shigehito Kamimura, Norio Takamoto, Takafumi Kudo, Junko Yamamoto, Yasunari Miyagi, Junichi Kodama, Kohji Taguchi, Mitsuo Yoshinouchi, and Kunihiro Kawanishi

Subjects
Pathology, medicine.medical_specialty, Uterine Cervical Neoplasms, Hysterectomy, Polymerase Chain Reaction, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pathological, Melanoma, Cyclin-Dependent Kinase Inhibitor p16, Vaginal Smears, business.industry, Obstetrics and Gynecology, DNA, Neoplasm, Sequence Analysis, DNA, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Microscopy, Electron, Uterine cervix, Female, Uterine Hemorrhage, Neoplasm Recurrence, Local, business
Abstract

We present case of a 57-year-old Japanese woman a 9 cm-size primary malignant melanoma of the uterine cervix. MRI demonstrated a low-signal T1-weighted spin echo image and hyperperfusion indicated by Gd-DTPA enhancement. The sequence! analysis of the MTS1/CDK4I gene revealed no deletion or mutation. The results of cytological, pathological, and electron microscopy tests are also presented.

Published
1998

81. Gamma-ray spectroscopy of 12C via the (π+,K+) reaction

Author

Hosomi, K., primary, Ajimura, S., additional, Aoki, K., additional, Dairaku, M., additional, Fu, Y.Y., additional, Fujioka, H., additional, Fukuda, T., additional, Futatsukawa, K., additional, Imoto, W., additional, Kakiguchi, Y., additional, Kawai, M., additional, Kinoshita, S., additional, Koike, T., additional, Ma, Y., additional, Maruyamai, N., additional, Mimori, M., additional, Minami, S., additional, Miura, Y., additional, Miwa, K., additional, Miyagi, Y., additional, Nagae, T., additional, Nakajima, D., additional, Noumi, H., additional, Shirotori, K., additional, Suzuki, T., additional, Takahashi, T., additional, Takahashi, T.N., additional, Tamura, H., additional, Tanida, K., additional, Terada, N., additional, Toyoda, A., additional, Tsukada, K., additional, Ukai, M., additional, and Zhou, S.H., additional

Published
2013
Full Text
View/download PDF

82. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study

Author

van Grieken, N C T, primary, Aoyma, T, additional, Chambers, P A, additional, Bottomley, D, additional, Ward, L C, additional, Inam, I, additional, Buffart, T E, additional, Das, K, additional, Lim, T, additional, Pang, B, additional, Zhang, S L, additional, Tan, I B, additional, Carvalho, B, additional, Heideman, D A M, additional, Miyagi, Y, additional, Kameda, Y, additional, Arai, T, additional, Meijer, G A, additional, Tsuburaya, A, additional, Tan, P, additional, Yoshikawa, T, additional, and Grabsch, H I, additional

Published
2013
Full Text
View/download PDF

86. Kaon photoproduction on the deuteron at Sendai

Author

Futatsukawa, K., primary, Beckford, B., additional, Bydžzovsky′, P., additional, Fujibayashi, T., additional, Fujii, Y., additional, Hashimoto, O., additional, Han, Y.C., additional, Hirose, K., additional, Hosomi, K., additional, Iguchi, A., additional, Ishikawa, T., additional, Kanda, H., additional, Kaneta, M., additional, Kawama, D., additional, Kawasaki, T., additional, Kiyokawa, S., additional, Koike, T., additional, Konno, O., additional, Maeda, K., additional, Maruyama, N., additional, Miwa, K., additional, Miyagi, Y., additional, Nakamura, S.N, additional, Sasaki, A., additional, Shirotori, K., additional, Sotona, M., additional, Suzuki, K., additional, Tamae, T., additional, Tamura, H., additional, Terada, N., additional, Tsukada, K., additional, and Yamazaki, H., additional

Published
2012
Full Text
View/download PDF

90. Neutral Kaon Photo-Production in the Threshold Energy Region

Author

Beckford, B., primary, Bydzovsky, P., additional, Fujibayashi, J., additional, Fujii, T., additional, Fujii, Y., additional, Futatsukawa, K., additional, Gogami, T., additional, Hashimoto, O., additional, Han, Y. C., additional, Hirose, K., additional, Hosomi, K., additional, Iguchi, A., additional, Ishikawa, T., additional, Kanda, H., additional, Kaneta, M., additional, Kawama, D., additional, Kawasaki, T., additional, Kiyokawa, S., additional, Koike, T., additional, Maeda, K., additional, Maruyama, N., additional, Miwa, K., additional, Miyagi, Y., additional, Nakamura, S. N., additional, Sasaki, A., additional, Shimizu, H., additional, Shirotori, K., additional, Suzuki, K., additional, Tamae, T., additional, Tamura, H., additional, Terada, N., additional, Tsukada, K., additional, Yamazaki, H., additional, Hosaka, Atsushi, additional, Khemchandani, Kanchan, additional, Nagahiro, Hideko, additional, and Nawa, Kanabu, additional

Published
2011
Full Text
View/download PDF

91. Abstract P1-11-13: Triple Negative or HER2 Positive Subtypes of Breast Cancer Groups Are Chemo-Sensitive, but Higher Rate of Brain Metastasis Contributes Poorer Prognosis

Author

Tokudome, N, primary, Ito, Y, additional, Takahashi, S, additional, Taira, S, additional, Tsutsumi, C, additional, Kobayashi, K, additional, Oto, M, additional, Ito, M, additional, Inoue, K, additional, Kuwayama, A, additional, Nakayama, Y, additional, Miyagi, Y, additional, Osako, T, additional, Horii, R, additional, Akiyama, F, additional, Iwase, T, additional, and Hatake, K., additional

Published
2010
Full Text
View/download PDF

96. Response to Neoadjuvant Chemotherapy of Triple Negative Breast Cancer.

Author

Tokudome, N., primary, Ito, Y., additional, Takahashi, S., additional, Sugihara, T., additional, Hosonaga, M., additional, Iwasaki, R., additional, Hattori, M., additional, Fukuda, T., additional, Mitsuhashi, K., additional, Kobayashi, K., additional, Taira, S., additional, Saito, Y., additional, Fukada, I., additional, Ueki, N., additional, Tsutsumi, C., additional, Miyagi, Y., additional, Iwase, T., additional, Osako, T., additional, Horii, R., additional, Akiyama, F., additional, and Hatake, K., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results